Search clinical trials for: a proliferation-inducing ligand

Total 497877 results

Hospices Civils de Lyon

Completed

Study of the Effects of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent Provirus (FXReservoir)

Hiv

France
Chang Gung Memorial Hospital

Completed

The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Metastatic Prostate Cancer

Taiwan
Peking University Third Hospital

Completed

The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine

Spinal Tumor

China
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma

United States
Theracos

Completed

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Type 2 Diabetes Mellitus

United States, France, Spain, Japan
National Cancer Institute (NCI)

Terminated

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Cancer | Cancer of Pancreas

United States
Theracos

Completed

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Advanced Solid Tumors

Tumors

France, United States, Denmark, Ireland, Italy, Turkey, United Kingdom, Canada, Brazil, Spain, Poland, Netherlands, Germany, Russian Federation, Austria, Finland, Norway, Switzerland
Ecarf Institute GmbH
Bencard Allergie GmbH

Completed

Impact of a Novel Immune Modulating Dietary Supplement on House Dust Mite Induced Allergic Rhinoconjunctivitis

Allergic Rhinitis | Dust Mite Allergy

Germany
University Health Network, Toronto

Withdrawn

LIpitor and biGuanide to Androgen Delay Trial (LIGAND)

Prostate Cancer

Canada
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Neoplasms | Head and Neck Neoplasms | Colorectal Neoplasms

Australia, Hong Kong
German Breast Group
AstraZeneca; Celgene

Completed

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)

Breast Cancer

Germany
AbbVie

Terminated

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Cancer | Non Small Cell Lung Cancer

United States
University of Wisconsin, Madison
Madison Vaccines Incorporated

Completed

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Prostate Cancer

United States
University Hospital, Bordeaux
University of Bordeaux

Completed

Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer (IMMUN VESSIE)

Bladder Cancer

France
Assiut University

Unknown

Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain

Chronic Pain

Egypt
Assistance Publique - Hôpitaux de Paris

Completed

Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin (CARSKIN)

Carcinoma, Squamous Cell

France
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (COURSE)

Venous Thromboembolism

Poland, Bulgaria, Latvia, Lithuania, Ukraine
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Breast Cancer
Assiut University

Unknown

Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer

Programmed Cell Death 1

Egypt
Jonsson Comprehensive Cancer Center

Completed

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer (MSG PSMA PET)

Prostate Carcinoma

United States
Daiichi Sankyo, Inc.
Syneos Health

Completed

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

Fibromyalgia

Spain, United States, Poland, Bulgaria, South Africa, Hungary, Czechia, Romania
Nantes University Hospital

Unknown

Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy

Bullous Pemphigoid | Immunotherapy | Programmed Cell Death Ligand 1

France
Advanced Accelerator Applications

Completed

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) (PROfind)

Prostate Cancer Metastatic

United States
Mayo Clinic

Terminated

Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand

Ovarian Cancer

United States
Nucorion Pharmaceuticals, Inc.
Medpace, Inc.; Ligand Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects

Hepatitis B

United States
Dana-Farber Cancer Institute

Withdrawn

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Soft Tissue Sarcoma

United States
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery (PSMA vs AXUMIN)

Recurrent Prostate Carcinoma

United States
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.

Antibiotic

China
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

Triple Negative Breast Neoplasms
Kiang Wu Hospital

Completed

PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Melanoma
Massachusetts General Hospital
Cedars-Sinai Medical Center; ALS Association; The Methodist Hospital Research...

Completed

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis (TRACK-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Malignant Melanoma
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

PD-L1 Positive Non-small Cell Lung Cancer
Groupe Français de Pneumo-Cancérologie

Completed

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC)

Large Cell Lung Cancer | Neuroendocrine Carcinoma of Lung (Diagnosis)

France
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand

Hypoglycemia

United States
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
Assiut University

Unknown

Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM

Glioblastoma Multiforme
Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Solid Tumor

United States, Spain, Canada, United Kingdom, Denmark, France, Germany, Israel, Italy, Netherlands, Switzerland
Merck Sharp & Dohme LLC

Withdrawn

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Esophageal Neoplasms

China
Assistance Publique - Hôpitaux de Paris

Unknown

NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL) (NADRANK-1)

Diabetes type2 | NAFLD | NASH - Nonalcoholic Steatohepatitis
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA)

Leukemia | Leukemia, B-Cell, Chronic

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

Leukemia

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (BIRCH)

Non-Small Cell Lung Cancer

United States, Belgium, Hong Kong, Italy, Slovenia, Australia, Canada, Bulgaria, Germany, France, Georgia, Singapore, Spain, Bosnia and Herzegovina, Switzerland, Turkey, Japan, United Kingdom, Netherlands
Hoffmann-La Roche

Completed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma (IMmotion150)

Renal Cell Carcinoma

United States, Spain, Czechia, United Kingdom, Romania, France, Italy, Germany, Poland
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)

Cancer, Solid Tumor
National Cancer Institute (NCI)

Completed

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Rhabdomyosarcoma | Ewing's Sarcoma

United States

3

Subscribe